{"entity":{"id":"favezelimab","kind":"drug","name":"Favezelimab","aka":[],"tldr":"Favezelimab is Merck's LAG-3 antibody, tested with pembrolizumab in phase 3 trials in colorectal cancer and classical Hodgkin lymphoma; the colorectal trial did not succeed.","summary":"Merck's favezelimab (MK-4280) blocks LAG-3, the second checkpoint validated by relatlimab in melanoma. Coformulated with pembrolizumab as MK-4280A, it entered phase 3 trials in previously treated microsatellite-stable colorectal cancer, where the trial did not meet its overall survival endpoint, and in relapsed classical Hodgkin lymphoma after PD-1 therapy. Registered phase 3 trials remain on ClinicalTrials.gov.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Favezelimab","url":"https://clinicaltrials.gov/search?intr=MK-4280"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","hodgkin-lymphoma"],"sections":[],"technologies":["checkpoint-inhibitor","lag3-blockade"],"targets":["lag3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03486873"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"MK-4280","modality":"Anti-LAG-3 monoclonal antibody, intravenous, also coformulated with pembrolizumab (MK-4280A)","mechanism":"Blocks the LAG-3 checkpoint on exhausted T cells; given with PD-1 blockade to overcome resistance to pembrolizumab alone.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/favezelimab/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"lag3-blockade","kind":"technology","name":"LAG-3 blockade","route":"/technologies/lag3-blockade/"}],"target":[{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/"}],"trial":[{"id":"nct05845814","kind":"trial","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","route":"/trials/nct05845814/"},{"id":"nct04895722","kind":"trial","name":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ","route":"/trials/nct04895722/"},{"id":"nct03486873","kind":"trial","name":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb","route":"/trials/nct03486873/"},{"id":"nct04938817","kind":"trial","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","route":"/trials/nct04938817/"},{"id":"nct04626479","kind":"trial","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","route":"/trials/nct04626479/"},{"id":"nct04626518","kind":"trial","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","route":"/trials/nct04626518/"}]}}